12:00 AM
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Regorafenib: Phase III started

Bayer began the double-blind Phase III GRID trial to compare 160 mg oral regorafenib given daily for the first 3 weeks of a 28-day cycle plus best supportive care (BSC) vs. placebo plus BSC in about 170 patients whose cancer has...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >